ME03034B - Jedinjenja [1 ,2 ,4]triazol0[1 ,5-c]hinazol/n-5-amina supstiтuisana sa heterobiciklo pogodna za lečenje ili prevenciju poremećaja centralnog nervnog sistema - Google Patents

Jedinjenja [1 ,2 ,4]triazol0[1 ,5-c]hinazol/n-5-amina supstiтuisana sa heterobiciklo pogodna za lečenje ili prevenciju poremećaja centralnog nervnog sistema

Info

Publication number
ME03034B
ME03034B MEP-2018-97A MEP201897A ME03034B ME 03034 B ME03034 B ME 03034B ME P201897 A MEP201897 A ME P201897A ME 03034 B ME03034 B ME 03034B
Authority
ME
Montenegro
Prior art keywords
heterobicyclo
quinazolin
triazolo
substituted
amine compounds
Prior art date
Application number
MEP-2018-97A
Other languages
German (de)
English (en)
French (fr)
Unknown language (me)
Inventor
Amjad Ali
Michael Man-Chu Lo
Yeon-Hee Lim
Andrew Stamford
Rongze Kuang
Paul Tempest
Younong Yu
Xianhai Huang
Timothy J Henderson
Jae-Hun Kim
Christopher Boyce
Pauline Ting
Junying Zheng
Edward Metzger
Nicolas Zorn
Dong Xiao
Gioconda V Gallo
Walter Won
Heping Wu
Qiaolin Deng
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of ME03034B publication Critical patent/ME03034B/me

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
MEP-2018-97A 2012-12-28 2013-12-20 Jedinjenja [1 ,2 ,4]triazol0[1 ,5-c]hinazol/n-5-amina supstiтuisana sa heterobiciklo pogodna za lečenje ili prevenciju poremećaja centralnog nervnog sistema ME03034B (me)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/CN2012/087865 WO2014101120A1 (en) 2012-12-28 2012-12-28 Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
PCT/CN2013/076853 WO2014101373A1 (en) 2012-12-28 2013-06-06 Heterobicyclo-substituted-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds for treatment of central nervous system disorder
EP13866588.0A EP2945632B1 (en) 2012-12-28 2013-12-20 Heterobicyclo-substituted-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds suitable for treatment or prevention of central nervous system disorders
PCT/US2013/076781 WO2014105666A1 (en) 2012-12-28 2013-12-20 Heterobicyclo-substituted-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties

Publications (1)

Publication Number Publication Date
ME03034B true ME03034B (me) 2018-10-20

Family

ID=51019745

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2018-97A ME03034B (me) 2012-12-28 2013-12-20 Jedinjenja [1 ,2 ,4]triazol0[1 ,5-c]hinazol/n-5-amina supstiтuisana sa heterobiciklo pogodna za lečenje ili prevenciju poremećaja centralnog nervnog sistema

Country Status (22)

Country Link
US (2) US9708347B2 (OSRAM)
EP (1) EP2945632B1 (OSRAM)
JP (1) JP6306049B2 (OSRAM)
KR (1) KR102165113B1 (OSRAM)
AU (1) AU2013370977B2 (OSRAM)
BR (1) BR112015015468B8 (OSRAM)
CA (1) CA2896056C (OSRAM)
CY (1) CY1120258T1 (OSRAM)
DK (1) DK2945632T3 (OSRAM)
ES (1) ES2667477T3 (OSRAM)
HR (1) HRP20180678T1 (OSRAM)
HU (1) HUE037950T2 (OSRAM)
LT (1) LT2945632T (OSRAM)
ME (1) ME03034B (OSRAM)
MX (1) MX370017B (OSRAM)
NO (1) NO2945632T3 (OSRAM)
PL (1) PL2945632T3 (OSRAM)
PT (1) PT2945632T (OSRAM)
RS (1) RS57162B1 (OSRAM)
RU (2) RU2671628C2 (OSRAM)
SI (1) SI2945632T1 (OSRAM)
WO (3) WO2014101120A1 (OSRAM)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3253390B1 (en) * 2015-02-06 2022-04-13 Merck Sharp & Dohme Corp. Aminoquinazoline compounds as a2a antagonist
EP3307067B1 (en) * 2015-06-11 2022-11-02 Merck Sharp & Dohme LLC Aminopyrazine compounds with a2a antagonist properties
WO2017008205A1 (en) 2015-07-10 2017-01-19 Merck Sharp & Dohme Corp. Substituted aminoquinazoline compounds as a2a antagonist
WO2017034994A1 (en) 2015-08-21 2017-03-02 Portola Pharmaceuticals, Inc. Composition and methods of use of novel phenylalanine small organic compounds to directly modulate pcsk9 protein activity
HK1257102A1 (zh) 2015-08-21 2019-10-11 Portola Pharmaceuticals, Inc. 苯基哌嗪前蛋白转化酶枯草杆菌蛋白酶/kexin9型(pcsk9)调节剂及其应用
HK1260897A1 (zh) 2015-08-21 2019-12-27 Portola Pharmaceuticals, Inc. 使用四氢异喹啉小分子来结合并调节pcsk9的蛋白活性的组合物和方法
WO2017107087A1 (en) * 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. 6, 7-dihydro-5h-pyrrolo [3, 4-b] pyridin-5-oneallosteric modulators of the m4 muscarinic acetylcholine receptor
WO2017107089A1 (en) 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor
ES2789756T3 (es) 2015-12-23 2020-10-26 Merck Sharp & Dohme Moduladores alostéricos de 6,7-dihidro-5H-pirrolo[3,4-b]piridin-5-ona del receptor de acetilcolina muscarínico M4
US20190119236A1 (en) 2016-02-23 2019-04-25 Portola Pharmaceuticals, Inc. Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)
WO2018112843A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
WO2018112842A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor
CN108884061B (zh) 2017-01-13 2021-11-16 江苏恒瑞医药股份有限公司 1,2,4-三嗪-3-胺类衍生物、其制备方法及其在医药上的应用
SG11201907909TA (en) 2017-02-27 2019-09-27 Betta Pharmaceuticals Co Ltd Fgfr inhibitor and application thereof
CN109963854B (zh) 2017-03-16 2022-04-12 江苏恒瑞医药股份有限公司 杂芳基并[4,3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用
EP3686199B9 (en) 2017-09-28 2022-12-07 Cstone Pharmaceuticals (Suzhou) Co., Ltd. Fused ring derivative as a2a receptor inhibitor
US11498923B2 (en) 2017-12-13 2022-11-15 Merck Sharp & Dohme Llc Substituted imidazo[1,2-c]quinazolines as A2A antagonists
CA3089159A1 (en) 2018-02-06 2019-08-15 Jiangsu Hengrui Medicine Co., Ltd. Pyrazolo[1,5-a][1,3,5]triazine-2-amine derivative, preparation method therefor and medical use thereof
WO2020106560A1 (en) 2018-11-20 2020-05-28 Merck Sharp & Dohme Corp. Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
KR20210093964A (ko) 2018-11-20 2021-07-28 머크 샤프 앤드 돔 코포레이션 치환된 아미노 트리아졸로피리미딘 및 아미노 트리아졸로피라진 아데노신 수용체 길항제, 제약 조성물 및 그의 용도
US12263171B2 (en) 2018-11-30 2025-04-01 Merck Sharp & Dohme Llc 7-, 8-, and 10-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use
CR20210271A (es) 2018-11-30 2021-07-14 Merck Sharp & Dohme Derivados de amino triazolo quinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmacéuticas y su uso
CA3126735A1 (en) 2019-01-11 2020-07-16 Omeros Corporation Methods and compositions for treating cancer
AR117844A1 (es) 2019-01-22 2021-09-01 Merck Patent Gmbh Derivados de tiazolopiridina como antagonistas del receptor de adenosina
JP7066913B2 (ja) 2019-03-26 2022-05-13 ノベルファーマ株式会社 持続型脂肪酸結合GnRH誘導体及びこれを含む薬剤学的組成物
FI4097099T3 (fi) 2020-02-07 2024-07-30 Gasherbrum Bio Inc Heterosyklisiä glp-1-agonisteja
WO2022020550A1 (en) * 2020-07-24 2022-01-27 Merck Sharp & Dohme Corp. Adenosine a2a and a2b receptor dual antagonists for immuno-oncology
WO2022020552A1 (en) * 2020-07-24 2022-01-27 Merck Sharp & Dohme Corp. Adenosine a2a and a2b receptor dual antagonists for immuno-oncology
CN112159411A (zh) * 2020-10-15 2021-01-01 南京工业大学 一种三氟甲基取代嘧啶并[1,3]二氮杂*化合物及其制备方法
US12115154B2 (en) 2020-12-16 2024-10-15 Srx Cardio, Llc Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)
AU2023252914A1 (en) 2022-04-13 2024-10-17 Arcus Biosciences, Inc. Combination therapy for treating trop-2 expressing cancers
IL322686A (en) 2023-02-16 2025-10-01 Gasherbrum Bio Inc Heterocyclic glp-1 agonists
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0181282A1 (de) * 1984-10-01 1986-05-14 Ciba-Geigy Ag Triazolochinazolinverbindungen
US4713383A (en) * 1984-10-01 1987-12-15 Ciba-Geigy Corporation Triazoloquinazoline compounds, and their methods of preparation, pharmaceutical compositions, and uses
IT1264901B1 (it) 1993-06-29 1996-10-17 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina
CA2144330A1 (en) * 1993-07-27 1995-02-09 Fumio Suzuki A therapeutic agent for parkinson's disease
JPH10501812A (ja) * 1994-06-20 1998-02-17 スミスクライン・ビーチャム・コーポレイション エンドセリン受容体拮抗薬
US5571775A (en) 1994-07-11 1996-11-05 Dowelanco N-aryl[1,2,4]triazolo[1,5-a]pyridine-2-sulfonamide herbicides
IT1277392B1 (it) 1995-07-28 1997-11-10 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
IT1291372B1 (it) 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
US5929106A (en) * 1997-10-27 1999-07-27 Smithkline Beecham Corporation Endothelin receptor antagonists
EP1283839B1 (en) * 2000-05-26 2005-04-20 Schering Corporation Adenosine a2a receptor antagonists
EP1293029A1 (en) * 2000-06-20 2003-03-19 Alexander Ellison Rees Electrical drive line
US6358964B1 (en) * 2000-07-26 2002-03-19 King Pharmaceuticals Research And Development, Inc. Adenosine, A3 receptor modulators
GB0100624D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
AU2003244649A1 (en) * 2002-07-25 2004-02-23 Pharmacia Italia Spa Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
BR0317436A (pt) * 2002-12-19 2005-11-16 Schering Corp Usos de antagonistas do receptor a2a de adenosina
DE602004018637D1 (de) * 2003-04-09 2009-02-05 Biogen Idec Inc A2a-adenosinrezeptorantagonisten
MY139344A (en) * 2003-04-23 2009-09-30 Schering Corp 2-alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine a2a receptor antagonists
PE20070521A1 (es) 2005-09-23 2007-07-13 Schering Corp 7-[2-[4-(6-FLUORO-3-METIL-1,2-BENCISOXAZOL-5-IL)-1-PIPERAZINIL]ETIL]-2-(1-PROPINIL)-7H-PIRAZOL-[4,3-E]-[1,2,4]-TRIAZOL-[1,5-C]-PIRIMIDIN-5-AMINA COMO ANTAGONISTA DEL RECEPTOR DE ADENOSINA A2a
JP2010509189A (ja) 2006-06-26 2010-03-25 シェーリング コーポレイション アデノシンA2aレセプターアンタゴニスト
WO2009032754A2 (en) 2007-08-31 2009-03-12 Kalypsys, Inc. Heterocyclodiazepine cannabinoid receptor modulators for treatment of disease
EP2210891A1 (en) * 2009-01-26 2010-07-28 Domain Therapeutics New adenosine receptor ligands and uses thereof
EP2509983B1 (en) * 2009-11-16 2014-09-17 Merck Sharp & Dohme Corp. FUSED TRICYCLIC COMPOUNDS WITH ADENOSINE A2a RECEPTOR ANTAGONIST ACTIVITY
WO2012135084A1 (en) * 2011-03-31 2012-10-04 Merck Sharp & Dohme Corp. METABOLITES OF 2-(FURAN-2-YL)-7-(2-(4-(4-(2-METHOXYETHOXY)PHENYL)PIPERAZIN-1-YL)ETHYL)-7H-PYRAZOLO[4,3-e][1,2,4]TRIAZOLO[1,5-c]PYRIMIDIN-5-AMINE AND THEIR UTILITY AS ADENOSINE A2a RECEPTOR ANTAGONISTS
WO2014101113A1 (en) 2012-12-28 2014-07-03 Merck Sharp & Dohme Corp. Piperazine-substituted 7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties

Also Published As

Publication number Publication date
NO2945632T3 (OSRAM) 2018-08-04
BR112015015468A2 (pt) 2017-07-11
WO2014101373A1 (en) 2014-07-03
RU2018136104A3 (OSRAM) 2022-04-05
KR20150100879A (ko) 2015-09-02
MX2015008481A (es) 2015-09-23
JP6306049B2 (ja) 2018-04-04
LT2945632T (lt) 2018-05-25
PL2945632T3 (pl) 2018-07-31
CA2896056A1 (en) 2014-07-03
KR102165113B1 (ko) 2020-10-13
RU2671628C2 (ru) 2018-11-06
ES2667477T3 (es) 2018-05-11
RU2015131148A (ru) 2017-02-03
EP2945632A4 (en) 2016-09-14
CY1120258T1 (el) 2019-07-10
RU2018136104A (ru) 2018-11-21
HUE037950T2 (hu) 2018-09-28
US20150361098A1 (en) 2015-12-17
EP2945632B1 (en) 2018-03-07
WO2014105666A1 (en) 2014-07-03
CA2896056C (en) 2020-11-10
US20170197991A1 (en) 2017-07-13
PT2945632T (pt) 2018-05-22
US9708347B2 (en) 2017-07-18
MX370017B (es) 2019-11-28
JP2016504363A (ja) 2016-02-12
DK2945632T3 (en) 2018-05-22
EP2945632A1 (en) 2015-11-25
AU2013370977B2 (en) 2017-12-14
AU2013370977A1 (en) 2015-07-09
WO2014101120A1 (en) 2014-07-03
SI2945632T1 (en) 2018-05-31
RS57162B1 (sr) 2018-07-31
BR112015015468B1 (pt) 2021-10-26
HRP20180678T1 (hr) 2018-06-01
BR112015015468B8 (pt) 2023-04-25
US10011615B2 (en) 2018-07-03

Similar Documents

Publication Publication Date Title
ME03034B (me) Jedinjenja [1 ,2 ,4]triazol0[1 ,5-c]hinazol/n-5-amina supstiтuisana sa heterobiciklo pogodna za lečenje ili prevenciju poremećaja centralnog nervnog sistema
IL234485A (en) Compounds based on imidazo [2,1 – b] pyridazine
AP3709A (en) Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
ZA201506570B (en) 2-phenylimidazo[1,2-a]pyrimidines as imaging agents
ZA201408843B (en) Imidazo[1,2-b]pyridazine derivative as kinase inhibitor
ZA201304757B (en) Imidazo [4,5-c] quinolin-2-one compound and its use as p13 kinase/mtor dual inhibitor
AP3751A (en) Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
SG11201403909RA (en) Pde9 inhibitors with imidazo triazinone backbone
IL229993A (en) 8 - Alkoxy [1,2,4] triazolo [5,1 – c] pyrimidine– 2
IL243092B (en) New triazolo[d–4,5]pyrimidine histories
SG11201401342VA (en) 5,7-substituted-imidazo[1,2-c]pyrimidines
EP2938344A4 (en) PIPERAZINE-SUBSTITUTED [1,2,4] TRIAZOLO [1,5-C] QUINAZOLINE-5-AMINE COMPOUNDS WITH A2A ANTAGONISTIC PROPERTIES
ZA201406323B (en) Triazolo[4,5-d]pyrimidine derivatives
EP2739627A4 (en) 2,3-DIHYDROIMIDAZO [1,2-C] PYRIMIDIN-5 (1H) -ONE COMPOUNDS AND USE AS INHIBITORS OF LP-PLA2
ZA201208616B (en) Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
ZA201304074B (en) Pyrazino[2,3-d]isoxazole derivative
GB201215033D0 (en) Diazepinone derivatives
GB2502329B (en) Pressurizable injection seat
GB201219129D0 (en) Triazolo(4,5-d)pyrmindine compounds
AU345494S (en) Alu-sofa 2-seater with one armrest
PH22012000559U1 (en) Multi-purpose stool
AU345495S (en) Alu-sofa 2-seater w/o armrest
GB201108072D0 (en) The juvenile judge
PH32012000628S1 (en) Multi-purpose hacksaw
PH22012000475U1 (en) Multi-purpose hacksaw